Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Inc.

Division of Johnson & Johnson
www.janssen-ortho.com

Latest From Janssen Inc.

Impersonal Medicine: IC/BPS And How An Orphan Indication Becomes A Common Disease

US FDA advisory committee recommendation to combine interstitial cystitis and bladder pain syndrome patients in clinical trials is an interesting example of encouraging drug development by broadening the patient population. That runs counter to the personalized medicine mantra of narrowing patient populations based on mechanism of action.

Advisory Committees Rare Diseases

Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation

Bayer Shrugs Off Xofigo Sales Pressure From Study Halt

Amid turmoil at Bayer's R&D unit, the company revealed that a Phase III trial of Xofigo had thrown up a safety issue for the product. Bayer insists peaks sales will be unaffected, but what had been a large potential new patient population now looks unlikely.

Clinical Trials Research & Development

AMBER Data Support Green Light For Janssen's Symtuza

More Phase III data for Janssen's first once-daily single tablet containing four drugs for use against HIV Symtuza support its use in treatment-naïve patients; the product awaits US approval.

Clinical Trials Research & Development
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register